American Thoracic Society - Sanofi Investor Call

Potential breakthrough medicines beyond Type 2 COPD Itepekimab • • Potent IL-33 blocker with best-in-class and first-in-class potential Unprecedented exacerbation reduction in former smokers shown in phase 2, positive interim analysis covering AERIFY 1 & 2 FDA Fast Track Designation status, pivotal data in 2025 Amlitelimab, rilzabrutinib and SAR'765 are under investigation and not yet approved by any regulatory agency. 43 ATS Investor Call Asthma SAR'765 • • . Leveraging two proven pathways Exciting results of SAR'765 on FeNO suggest a synergistic effect Potential to suppress airway inflammation preserve lung function, and disease modify . Phase 2b starting H2 2023 Amlitelimab & rilzabrutinib • Phase 2 readouts in 2024 sanofi

View entire presentation